tiprankstipranks
Trending News
More News >
Pluri (PLUR)
NASDAQ:PLUR
Advertisement

Pluri (PLUR) Price & Analysis

Compare
973 Followers

PLUR Stock Chart & Stats

$4.25
-$0.22(-4.74%)
At close: 4:00 PM EST
$4.25
-$0.22(-4.74%)

Pluri News

PLUR FAQ

What was Pluri’s price range in the past 12 months?
Pluri lowest stock price was $3.33 and its highest was $7.13 in the past 12 months.
    What is Pluri’s market cap?
    Pluri’s market cap is $34.66M.
      When is Pluri’s upcoming earnings report date?
      Pluri’s upcoming earnings report date is Feb 11, 2025 which is 251 days ago.
        How were Pluri’s earnings last quarter?
        Currently, no data Available
        Is Pluri overvalued?
        According to Wall Street analysts Pluri’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Pluri pay dividends?
          Pluri does not currently pay dividends.
          What is Pluri’s EPS estimate?
          Pluri’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does Pluri have?
          Pluri has 8,155,948 shares outstanding.
            What happened to Pluri’s price movement after its last earnings report?
            Currently, no data Available
            Which hedge fund is a major shareholder of Pluri?
            Currently, no hedge funds are holding shares in PLUR

            Company Description

            Pluri

            Pluri Inc., a biotechnology company, focuses on the development of placenta-based cell therapy product candidates for the treatment of multiple inflammatory, muscle injuries, and hematologic conditions. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trials for the muscle recovery after surgery for hip fracture; in Phase II clinical trails for the treatment of acute respiratory distress syndrome associated with COVID-19; and in Phase I/II clinical trial for treatment of steroid-refractory graft versus host disease. It also develops PLX-R18 for incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as a solution for the treatment of acute radiation syndrome. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.
            Similar Stocks
            Company
            Price & Change
            Follow
            IGC Pharma
            Iterum Therapeutics
            PolyPid
            AN2 Therapeutics, Inc.
            Mural Oncology Plc

            Ownership Overview

            26.81%0.03%0.15%72.62%
            26.81% Insiders
            0.15% Other Institutional Investors
            72.62% Public Companies and
            Individual Investors

            Options Prices

            Currently, No data available
            ---
            Popular Stocks
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis